In the wake of COVID-19, government officials around the world face unprecedented decisions about when and to what extent they should reopen their respective societies before effective anti-viral medications or vaccines have been developed, necessary regulatory approvals obtained, and those solutions are manufactured for public use. Fundamentally, such decisions will require a delicate balance between protecting public health and facilitating economic growth, which, as we have all been reminded this year, are deeply intertwined.
Patent
- Enablement
- Fee Shifting
- Litigation
- COVID IP Waiver Attempts are Becoming Harder to Justify
- Coons and Hirono Raise Concerns Over Pride in Patent Ownership Act Penalties
- The Fintiv Deception: Leahy’s Legislative ‘Fix’ is Unwarranted in Light of Sotera Wireless
- An Ax(le) Needs Grinding: Can the Federal Circuit Turn the Wheel?
- India’s Prius Judgment and Trans-Border Reputation of Trademarks
Recent Posts
- COVID IP Waiver Attempts are Becoming Harder to Justify
- Coons and Hirono Raise Concerns Over Pride in Patent Ownership Act Penalties
- The Fintiv Deception: Leahy’s Legislative ‘Fix’ is Unwarranted in Light of Sotera Wireless
- An Ax(le) Needs Grinding: Can the Federal Circuit Turn the Wheel?
- India’s Prius Judgment and Trans-Border Reputation of Trademarks